Marriott Vacations Worldwide stock slips premarket as VAC investors weigh $425 million cash-flow target

Marriott Vacations Worldwide stock slips premarket as VAC investors weigh $425 million cash-flow target

New York, Feb 27, 2026, 08:54 EST — Premarket

Shares of Marriott Vacations Worldwide Corp dropped 1.3% to $66.84 before the bell Friday, giving back a slice of the 17% surge from the prior session. The stock wrapped up Thursday at $67.73.

Investors are dissecting Marriott Vacations’ 2026 outlook, which puts a sharp focus on boosting cash and tightening expenses following a quarter weighed down by hefty write-downs. The company is projecting contract sales between $1.745 billion and $1.815 billion, and expects to generate adjusted free cash flow of $375 million to $425 million. CEO Matt Avril noted that fourth-quarter adjusted EBITDA came in “towards the high end” of their guidance range. Bottom line: Marriott Vacations swung to a $431 million net loss attributable to shareholders, hammered by $546 million in non-cash impairment charges. On the credit front, delinquencies dropped year-over-year for the fourth consecutive quarter, and the sales reserve stood at 12.7% of contract sales, excluding resales. Securities and Exchange Commission

Marriott Vacations, in its Feb. 26 investor deck, projected adjusted free cash flow—a non-GAAP metric tracking cash generation—could climb to $375 million to $425 million by 2026, up from $145 million in 2025. The presentation’s bridge chart showed the move driven by reduced inventory spending, changes in both financing and working capital, plus an extra $200 million to $250 million the company aims to collect from non-core asset sales over the next two years.

Thursday’s action proved choppy. Shares kicked off at $70.41, climbed to $73.37 before tumbling to a $66.01 low, and settled at $67.66. Trading volume reached roughly 1.65 million shares, Stock Analysis data show.

The company aimed for a streamlined process. In its Feb. 25 filing, it said the updated investor presentation would go live on its website, noting the slides might include information “that may be deemed material to investors.” But the company also made clear: it won’t file a fresh 8-K with every update to the deck. Securities and Exchange Commission

Still, management flagged that some turbulence could be ahead. On the call, CEO Avril cautioned the first half of 2026 “could easily be a little bumpy.” CFO Jason Marino added the company wrapped up 2025 with leverage at 4.2 times—“above where we want to be long term.” He also projected contract sales to slip by a few percentage points in Q1. The focus now: VPG, or volume per guest, as they cut back on tour volume in Asia and scale down development. Investing.com

Marriott Vacations carries a market value near $2.3 billion, with the stock moving in step with its sector as funding costs or consumer appetite shift. Shares of Hilton Grand Vacations and Travel + Leisure, two rivals in the timeshare space, both dropped roughly 2% in recent trading.

Now Wall Street looks for evidence the cash targets will hold up in practice—think loan performance, inventory expenses, and the timing of asset sales. The next look comes at the company’s earnings, set for April 30 according to Investing.com.

Michał Rogucki is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic developments. A graduate of Humboldt University of Berlin, he previously worked in investment research and market analysis before transitioning to financial journalism. He covers the trends and events that matter most to investors worldwide.

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Xylem

NYSE: XYL 94 / 100
#2 STRONG BUY

AerCap

NYSE: AER 92 / 100
#3 BUY ON WEAKNESS

Visa

NYSE: V 90 / 100
#4 BUY

Chevron

NYSE: CVX 86 / 100
#5 ACCUMULATE

UPS

NYSE: UPS 84 / 100
View full portfolio
Editorial model selection. Not personalised advice.
VeriSign stock price jumps 5% — what to watch for VRSN before the opening bell
Previous Story

VeriSign stock price jumps 5% — what to watch for VRSN before the opening bell

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears
Next Story

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears